drugset / Trial / NCT05500092
An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer
Phase 2
Active not recruiting
17 enrolled
Montefiore Medical Center
Bristol-Myers Squibb · collabPenn State University · collabWashington University School of Medicine · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
An open label, randomized study of neoadjuvant nivolumab and chemotherapy, with or without sub-ablative stereotactic body radiation therapy, for resectable stage IIA to IIIB non-small cell lung cancer
Timeline
- Start
- 2023-01-25
- Primary completion
- 2025-07-01
- Completion
- 2030-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Carboplatin | Small molecule | — | — |
| Background | Cisplatin | Other / unclassified | 75 mg/m2 | — |
| Background | Docetaxel | Small molecule | 75 mg/m2 | — |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | — |
| Background | Nivolumab | Monoclonal antibody | 360 mg | — |
| Background | Pemetrexed | Small molecule | 500 mg/m2 | — |